Drug profile

The FDA adverse-event record for [No Api/Abi]

33 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference [No Api/Abi]. Species, reactions, and outcomes follow.

#1379 of 2,679
by report volume (all drugs)
33
adverse-event reports
15.2%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, [No Api/Abi] ranks #1367 of 2679 by total reports (33). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#1367
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. [No Api/Abi] has 33 reports now versus 33 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to [No Api/Abi] changes

Signature read: death-coded share at 15.2% is the most distinctive stamp on [No Api/Abi]'s FDA AER row.

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
33
Total Reports
5
Deaths Reported
15.2%
Death-coded share of reports

Active Ingredients

[No Api/Abi]

Administration Routes

OralUnknown

Species Affected

Dog 20
Cat 12
Unknown 1

Most Affected Breeds

Domestic Shorthair 9
Retriever - Labrador 3
Poodle (unspecified) 2
Retriever - Golden 2
Chihuahua 2
Pug 1
Unknown 1
Poodle - Toy 1
Hound - Basset 1
Shepherd Dog - German 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 8
Weight loss 7
Anaemia NOS 6
Anorexia 4
Other abnormal test result NOS 4
Vomiting 4
Lethargy (see also Central nervous system depression in 'Neurological') 3
Death 3
Elevated symmetrical dimethylarginine (SDMA) 3
Abnormal cytology 3
Bacterial skin infection NOS 3
Seizure NOS 2

Outcome Breakdown

Ongoing
21 (65.6%)
Outcome Unknown
4 (12.5%)
Died
3 (9.4%)
Euthanized
2 (6.3%)
Recovered/Normal
2 (6.3%)

[No Api/Abi] Adverse Event Insights

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for [No Api/Abi] (#1379 of 2,679 by report volume); death-coded 15.2%. PlainBreed drug row · death-coded share stamp 15.2% · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →